SERD therapy has been extensively accepted and used as both monotherapy and in combination with other therapeutic agents. The potential of SERD therapy in breast cancer treatment is yet to be fully discovered, thus leaving a substantial scope of innovation and research in the field.
SERDs have shown significant potential to treat patients with endocrine-resistant breast cancer and naive patients with breast cancer.
North America currently dominates the global SERD therapeutics market. The global market was valued at $874.9 million in 2020, wherein North America held the largest share of 42.72%, followed by Asia-Pacific with 27.25%, Europe with 23.23%, and Rest-of-the-World with a 6.79% share.
SERD therapy has been extensively accepted and used as both monotherapy and in combination with other therapeutic agents. The potential of SERD therapy in breast cancer treatment is yet to be fully discovered, thus leaving a substantial scope of innovation and research in the field.
SERDs have shown significant potential to treat patients with endocrine-resistant breast cancer and naive patients with breast cancer.
North America currently dominates the global SERD therapeutics market. The global market was valued at $874.9 million in 2020, wherein North America held the largest share of 42.72%, followed by Asia-Pacific with 27.25%, Europe with 23.23%, and Rest-of-the-World with a 6.79% share.